Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1996-05-09
2000-09-12
Peselev, Elli
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
514 21, A61K 3170
Patent
active
061178500
ABSTRACT:
Methods for inducing mobilization of peripheral blood precursor cells, for elevating levels of peripheral blood precursor cells and facilitating hematopoietic reconstitution in a mammal are disclosed, comprising administering to the mammal an effective amount of an underivatized, aqueous soluble .beta.(1,3)-glucan in a triple helix conformation, which does not stimulate or prime the production of proinflammatory cytokines in vitro.
REFERENCES:
patent: 4739046 (1988-04-01), DiLuzio
patent: 4761402 (1988-08-01), Williams et al.
patent: 5532223 (1996-07-01), Jamas et al.
patent: 5554512 (1996-09-01), Lyman et al.
patent: 5637323 (1997-06-01), Wiltrout et al.
Czop, J.K., et al., "Perturbation of .beta.-Glucan Receptors on Human Neutrophils Initiates Phagocytosis and Leukotriene B.sub.4 Production", J. of Immunology, 141 (9):3170-3176 (1988).
Abel, G., and Czop, J.K, "Stimulation of Human Monocyte .beta.-Glucan Receptors by Glucan Particles Induces Production of TNF-.alpha. and IL-1.beta.", Intl. J. Immunopharmacol., 14(8):1363-1373 (1992).
Doita, M., et al., "Effect of Soluble Aminated .beta.-1, 3-d-Polyglucose on Human Monocytes: Stimulation of Cytokine and Prostaglandin E.sub.2 Production But Not Antigen-Presenting Function", J. of Leukocyte Biology, 49:342-351 (1991).
Cain, J.A., et al., "Role of Complete Receptor Type Three and Serum Opsonins in the Neutrophil Response to Yeast", Complement, 4:75-86 (1987).
Gallin, E.K., et al., "Comparative Effects of Particulate and Soluble Glucan on Macrophages of C3H/HeN and C3H/HeJ Mice", Int. J. Immunopharmacol., 14:173-183 (1992).
Brunke-Reese, D. and Mackin, W.M., "Enhanced Nitric Oxide (NO) Production by Peritoneal Macrophages Isolated from Rats Treated with PGG-Glucan (Betafectin.TM.)", Faseb J., 8:A216 Abstract No. 1244 (1994).
Poutsiaka, D.D., et al., "Cross-Linking of the .beta.-Glucan Receptor on Human Monocytes Results in Interleukin-1 Receptor Antagonist but not Interleukin-1 Production", Blood, 82(12):3695-3700 (1993).
Wakshull, E., et al., "Synergistic Stimulation of Myeloid Progenitor Cell Proliferation by a Novel .beta.-Glucan and GM-CSF", J. Cell Biochem. Suppl., 18:A222 (1994).
Mackin, W., et al., "Enhanced Microbicidal Activities of Human Peripheral Blood Monocytes and Neutrophils (PMN) After Pre-Treatment with PGG-Glucan, (Betafectin)", Faseb J., 8:A488, Abstract No. 2827 (1994).
Diamond, M.S., et al., "The I Doman is a Major Recognition Site on the Leukocyte Integrin Mac-1 (CD11b/CD18) for Four Distinct Adhesion Ligands", J. Cell. Biol., 120(4):1031-1043 (1993).
Wakshull, E., et al., "Characterization of PGG-Glucan Bindings to a .beta.-Glucan Receptor on Human Leukocytes", Faseb J., 10:A1338, Abstract No. 1954 (1996).
Czop, J.K., et al., "Isolation and Characterization of .beta.-Glucan Receptors on Human Mononuclear Phagocytes", J. Exp. Med., 173:1511-1520 (1991).
Szabo, T., et al., "Biochemical Properties of the Ligand-Binding 20-kDa Subunit of the .beta.-Glucan Receptors on Human Mononuclear Phagocytes", J. of Biological Chemistry, 270 (5):2145-2151 (1995).
Goldman, R., "Induction of a .beta.-1, 3-D-Glucan Receptor in P388D1 Cells Treated with Retinoic Acid or 1,25-Dihydroxyvitamin D.sub.3 ", Immunology, 63(2):319-324 (1988).
Goldman, R., "Characteristics of the .beta.-Glucan Receptor of Murine Macrophages", Experimental Cell Research, 174(2):481-490 (1988).
Thornton, B.P., et al., "Analysis of the Sugar Specificity and Molecular Location of the .beta.-Glucan-Binding Lectin Site of Complement Receptor Type 3 (CD11b/cd18).sup.1 ", J. Immunol., 156(3):1235-1246 (1996).
Konopski, Z, et al., "A Novel Immunomodulator Soluble Aminated .beta.-1,3-D-Glucan: Binding Characteristics to Mouse Peritoneal Macrophages", Biochem., Biophys. Acta, 1221(1):61-65 (1994).
Muller, A., et al., "Receptor Binding and Internalization of a Water-Soluble (1.fwdarw.3)-.beta.-D-Glucan Biologic Response Modifier in Two Monocyte/Macrophage Cell Lines.sup.1 ", J. Immunol., 156:3418-3425 (1996).
Engstad R.E., et al., "Specificity of a .beta.-Glucan Receptor on Macrophages from Atlantic Salmon (Salmo Salar L.)", Dev. Comp. Immunol., 18(5):397-408 (1994).
Muller, C.D., et al., "Functional .beta.-Glucan Receptor Expression by a Microglial Cell Line", Res. Immunol., 145:267-275 (1994).
Czop, J.K., et al., "Production and Isolation of Rabbit Anti-Idiotypic Antibodies Directed Against the Human Monocyte Receptor for Yeast .beta.-Glucans", J. of Immunology, 45:955-1001 (1990).
Demirer, T., "Optimization of Peripheral Blood Stem Cell Mobilization", Stem Cells, 14:106-116 (1996).
Stadtmauer, E.A., et al., "Peripheral Blood Progenitor Cell Generation and Harvesting", Seminars in Oncology, 22(3):291-300 (1995).
Browder, W., et al., "Beneficial Effect of Enhanced Macrophage Function in the Trauma Patient", Ann. Surg., 211(5):605-613 (1990).
Chihara, G., et al., "Lentinan as a Host Defence Potentiator (HDP)", Int. J. Immunotherapy, (4):145-154 (1989).
Pretus, H.A., et al., "Isolation, Physicochemical Characterization and Preclinical Efficacy Evaluation of Soluble Scleroglucan", J. of Pharmacology and Experimental Therapeutics, 500-510 (1991).
Williams, D.L., et al., "Development, Physicochemical Characterization and Preclinical Efficacy Evaluation of a Water Soluble Glucan Sulfate Derived From Saccharomyces Cerevisiae", Immunopharmacology, 22:139-156 (1991).
Patchen, M.L. and MacVittie, T.J., "Temporal Response of Murine Pluripotent Stem Cells and Myeloid and Erythroid Progenitor Cells to Low-Dose Glucan Treatment", Acta heamat., 70:281-288 (1983).
Patchen, M.L., et al., "Mobilization of Peripheral Blood Progenitor Cells by Betafectin PGG-Glucan", Experimental Hematology, 24 Abstract No. 43 (1996).
Patchen, M.L. and Lotzova, Modulation of Murine Hemopoiesis by Glucan, Exp. Hemat., 8(4):409-422 (1980).
Bleicher Paul
Patchen Myra L.
Peselev Elli
The Collaborative Group, Ltd.
LandOfFree
Mobilization of peripheral blood precursor cells by .beta.(1,3)- does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Mobilization of peripheral blood precursor cells by .beta.(1,3)-, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mobilization of peripheral blood precursor cells by .beta.(1,3)- will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-96232